Literature DB >> 20223566

Inside HDAC with HDAC inhibitors.

Philippe Bertrand1.   

Abstract

Histone deacetylase inhibitors are a large group of diverse molecules intrinsically able to inhibit cell proliferation in various cancer cell lines. Their apoptotic effects have been linked to the modulation in the expression of several regulatory tumor suppressor genes caused by the modified status of histone acetylation, a key event in chromatin remodelling. As the initial histone deacetylase activity of HDAC has been extended to other proteins, the possible other biological mechanisms modified by HDAC inhibitor treatments are still to be clarified. The need for HDAC isoform selective inhibitors is an important issue to serve this goal. This review discusses the approaches proposed by several research groups working on the synthesis of HDAC inhibitors, based on modelling studies and the way these findings were used to obtain new HDAC inhibitors with possible isoform selectivity. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223566     DOI: 10.1016/j.ejmech.2010.02.030

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  84 in total

1.  Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation.

Authors:  Pravin Bhansali; Christin L Hanigan; Robert A Casero; L M Viranga Tillekeratne
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

Review 2.  Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.

Authors:  Na'ama A Shein; Esther Shohami
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

3.  HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.

Authors:  P Peixoto; V Castronovo; N Matheus; C Polese; O Peulen; A Gonzalez; M Boxus; E Verdin; M Thiry; F Dequiedt; D Mottet
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

4.  HDAC1 and HDAC2 are differentially expressed in endometriosis.

Authors:  Maricarmen Colón-Díaz; Perla Báez-Vega; Miosotis García; Abigail Ruiz; Janice B Monteiro; Jessica Fourquet; Manuel Bayona; Carolina Alvarez-Garriga; Alexandra Achille; Edward Seto; Idhaliz Flores
Journal:  Reprod Sci       Date:  2012-02-16       Impact factor: 3.060

5.  Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

Authors:  Samuel Bouchet; Camille Linot; Dusan Ruzic; Danica Agbaba; Benoit Fouchaq; Joëlle Roche; Katarina Nikolic; Christophe Blanquart; Philippe Bertrand
Journal:  ACS Med Chem Lett       Date:  2019-05-09       Impact factor: 4.345

6.  Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.

Authors:  Benjamin E L Lauffer; Robert Mintzer; Rina Fong; Susmith Mukund; Christine Tam; Inna Zilberleyb; Birgit Flicke; Allegra Ritscher; Grazyna Fedorowicz; Roxanne Vallero; Daniel F Ortwine; Janet Gunzner; Zora Modrusan; Lars Neumann; Christopher M Koth; Patrick J Lupardus; Joshua S Kaminker; Christopher E Heise; Pascal Steiner
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

7.  Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

Authors:  Wenwen Duan; Jin Li; Elizabeth S Inks; C James Chou; Yuping Jia; Xiaojing Chu; Xiaoyang Li; Wenfang Xu; Yingjie Zhang
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

8.  Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Authors:  Shuai Gao; Jie Zang; Qianwen Gao; Xuewu Liang; Qinge Ding; Xiaoyang Li; Wenfang Xu; C James Chou; Yingjie Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-19       Impact factor: 3.641

Review 9.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

10.  Computational exploration of zinc binding groups for HDAC inhibition.

Authors:  Kai Chen; Liping Xu; Olaf Wiest
Journal:  J Org Chem       Date:  2013-04-29       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.